tirzepatide shortage fda update semaglutide Ends: What Patients Need to Know FDA sets compounding deadlines – Can you still compound Tirzepatide?

The Growing Epidemic The World Health Organization (WHO) defines overweight for Asians as a Body Mass Index (BMI) of 23 kg/m or higher and obesity as 27.5 kg/m or higherthresholds lower than global standards due to the higher body fat percentage in Asians at lower BMIs

It has been proven that glucagon-like peptide-1 receptor (GLP-1R) agonists control blood glucose concentrations through a multitude of mechanisms, such as increased satiety, slow stomach emptying, decreased glucagon secretion, and increased insulin synthesis/secretion

For appetite suppression, GLP-1s like Semaglutide and Tirzepatide remain the clinical standard

They also help with satiety, which aligns well with the appetite-suppressing effects of GLP-1 medications